Global Obstructive Sleep Apnea (OSA) Drugs Market
Global Obstructive Sleep Apnea (OSA) Drugs Market is a common type of sleep apnea which is characterized by the frequent cessation in breathing in deep sleep which can be occurred during the relaxation of muscles in the back of throat blocking the airway. These muscles help in supporting pharyngeal and oral structures such as uvula, soft palate, tonsils and tongue. Usually, 10-20 minutes of pausing in breathing if the airway is either partially or completely blocked that can lower the blood oxygen levels. The brain gets panic when this happens and rouses body to restart breathing. It can happen about 30 times an hour throughout the midnight which significantly disturbs the sleep cycles.
A surge in the prevalence of sleep apnea is majorly driving the growth of the sleep apnea treatment market. As per the National Commission on Sleeping Disorders Research, globally about 38,000 deaths are accounting annually owing to the cardiovascular problems associated with sleep apnea. Furthermore, growing geriatric population, rising lifestyle changes, growing home care acceptance coupled with the awareness of sleep disorders, improving healthcare infrastructure, an introduction of new technologies and innovative products are expected to fuel the growth of sleep apnea treatment market. However, strict regulatory procedures, side effects associated with the drugs, high competition in the market are expected to hamper the sleep apnea treatment market growth.
Increasing number of rehabilitation centres, awareness campaigns to assist patients with neurological disorders which have led to rising in the number of patients seeking treatments for neurological disorders. The risk of sleep apnea is greater in the age group of 50-60 years. According to UNO estimations in 2012, the geriatric population was about 810 Mn and it is anticipated to grow over 2000 Mn people by 2050 globally.
The Global Obstructive Sleep Apnea (OSA) Drugs Market is classified on the basis of drugs, distribution channel, and geography.
Based on drugs, the market is segmented into the following:
- CNS stimulants
Based on the distribution channel, the market is segmented into the following:
- Hospital pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of geographical regions, Global Obstructive Sleep Apnea (OSA) Drugs Market is classified as into five key regions as Asia- Pacific, North America, Europe, Middle East & Africa and Latin America. North America holds the largest share in the obstructive sleep apnea drugs market followed by Europe owing to the presence of the large geriatric population of the pool, high incidence and prevalence of obstructive sleep apnea, the existence of advanced healthcare technologies and infrastructure. Asia Pacific obstructive sleep apnea drugs market is expected to show significant growth rate due to increase in awareness about sleep apnea and several co-morbidities, growing public and private healthcare expenditure, a continuous launch of new products and technologies.
Obstructive Sleep Apnea (OSA) Drugs Market Key Players are Biogen, Inc (U.S)., Pfizer, Inc. (U.s), Johnson & Johnson Services, Inc. (U.S), Otsuka America Pharmaceutical, Inc. (U.S), Eli Lilly & Company (U.S), Merck & Co., Inc. (U.S), AstraZeneca (UK), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd.(Israel) and Shire Plc. (Ireland)
- In June 2016, In U.S Mylan launched Armodafinil Tablets of 50, 150 and 250 mg, the generic version of Cephalon’s Nuvigil.
- The report provides granular level information about the market size, regional market share, and forecast from 2018-2024
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario